
Harvard Bioscience, Inc.
HBIONASDAQHealthcareMedical - Instruments & Supplies
Latest quote
$7.47
−$0.07 · -0.93%
HBIO company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
46
Fair Value
Momentum
44
Neutral
Sentiment
51
Mixed
Risk resilience
33
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteHarvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- Headquarters
- US
- CEO
- John D. Duke
- Listed since
- Dec 7, 2000
- Employees
- 328
Market position
- Volume
- 10.66K
- 0.41× average
- Average volume
- 25.93K
- Average daily volume
- Market cap
- 33.74M USD
- Beta
- 1.49
- Market reference 1
Financials
Financial snapshot
Latest / TTMFinancial health
- Altman Z-score
- -2.58
- Piotroski F-score
- 5 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 86.55M USD | 94.14M USD | 112.25M USD | 113.34M USD | 118.9M USD |
| Cost of goods sold | 40.67M USD | 39.37M USD | 46.18M USD | 52.52M USD | 51.25M USD |
| Gross profit | 45.88M USD | 54.77M USD | 66.07M USD | 60.82M USD | 67.65M USD |
| Research and development | 8.83M USD | 10.41M USD | 11.76M USD | 12.33M USD | 10.8M USD |
| Selling, general, and administrative | 36.96M USD | 43.71M USD | 46.89M USD | 49.53M USD | 48.95M USD |
| Operating expenses | 46.51M USD | 60.98M USD | 64.18M USD | 67.75M USD | 65.59M USD |
| Interest expense | 4.92M USD | 3.21M USD | 3.59M USD | 2.55M USD | 1.54M USD |
| Depreciation and amortization | 5.95M USD | 6.98M USD | 7M USD | 7.58M USD | 7.62M USD |
| Operating income | −629K USD | −6.21M USD | 1.89M USD | −6.93M USD | 2.07M USD |
| Net income | −56.7M USD | −12.41M USD | −3.42M USD | −9.52M USD | −288K USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 45%
- 5 beats, 5 misses, 1 met estimate
- Average EPS surprise
- -282.19%
- 11 comparable reports
- Latest EPS result
- -0.14
- Estimate -0.21 · Beat by 33.33%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
5 ratingsRecent analyst actions
HBIO news
HBIO peers
ETFs holding HBIO
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI753.17K0.00%2.3T USD0.03%$378.24+0.44%
Vanguard Extended Market ETFVXF256.46K0.00%93.7B USD0.05%$245.53+0.82%
State Street SPDR S&P Emerging Markets Small Cap ETFEWX82.74K0.01%685.65M USD0.65%$72.22+0.25%
Dimensional - US Sustainability Core 1 ETFDFSU14.36K0.00%2.35B USD0.15%$48.20+0.52%
Dimensional - US Small Cap ETFDFAS10.31K0.00%15.92B USD0.26%$83.02+0.73%
Dimensional - US Core Equity 2 ETFDFAC7.77K0.00%49.31B USD0.17%$45.61+0.46%
Dimensional - US Core Equity 1 ETFDCOR7.01K0.00%3.51B USD0.14%$84.54+0.42%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 753.17K
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard Extended Market ETFVXF- Market value
- 256.46K
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
State Street SPDR S&P Emerging Markets Small Cap ETFEWX- Market value
- 82.74K
- Weight
- 0.01%
- AUM
- 685.65M USD
- Expense ratio
- 0.65%
- Price / 1D
- $72.22+0.25%
Dimensional - US Sustainability Core 1 ETFDFSU- Market value
- 14.36K
- Weight
- 0.00%
- AUM
- 2.35B USD
- Expense ratio
- 0.15%
- Price / 1D
- $48.20+0.52%
Dimensional - US Small Cap ETFDFAS- Market value
- 10.31K
- Weight
- 0.00%
- AUM
- 15.92B USD
- Expense ratio
- 0.26%
- Price / 1D
- $83.02+0.73%
Dimensional - US Core Equity 2 ETFDFAC- Market value
- 7.77K
- Weight
- 0.00%
- AUM
- 49.31B USD
- Expense ratio
- 0.17%
- Price / 1D
- $45.61+0.46%
Dimensional - US Core Equity 1 ETFDCOR- Market value
- 7.01K
- Weight
- 0.00%
- AUM
- 3.51B USD
- Expense ratio
- 0.14%
- Price / 1D
- $84.54+0.42%
Continue in GoAI
Research HBIOresearch.disclaimer








